Pfizer reported Q4 FY 2016 earnings of $0.47 per share (versus $0.53 in Q4 FY 2015), missing analysts' consensus estimate of $0.51.

The company's quarterly revenues amounted to $13.627 bln (-3% y/y), generally in-line with analysts' consensus estimate of $13.690 bln.

The company also issued in-line guidance for FY 2017, projecting EPS of 2.50-2.60 (versus analysts' consensus estimate of $2.60) and revenues of $52-54 bln (versus analysts' consensus estimate of $54.86 bln).

PFE fell to $30.88 (-1.37%) in pre-market trading.